GLP-1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters

The U.S. Food and Drug Administration has issued 30 warning letters to entities involved in the telehealth marketing of GLP-1 medications, signaling a major regulatory push for compliance in the virtual care space. This move highlights the agency's increasing scrutiny of how digital health platforms promote popular weight-loss treatments to consumers. For the telemedicine sector, these actions underscore the necessity of aligning marketing practices with federal safety and advertising standards. The enforcement serves as a warning to virtual care providers that high-growth pharmaceutical categories will face rigorous oversight as the industry expands.